Broncus Medical (02216.HK) Announces Annual Results for 2023
The treatment products R&D continue to lead, and product sales are steadily advancing. HANGZHOU, China, March 28, 2024 /PRNewswire/ -- On March 28, 2024, Broncus Medical (02216.HK) (the "Company" or "we" ) announced annual results for FY 2023. In 2023, Broncus Medical earned product sales of US...
Broncus has announced the acquisition of the entire interest in Hangzhou Jingliang
HANGZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Broncus(2216.HK) is pleased to announce that, onNovember 23 2023 Broncus Hangzhou (a whollyowned subsidiary of Broncus, as Transferee) has entered into the Equity Transfer Agreement with the shareholders of the Hangzhou Jingliang, to acquire 100% equ...
Broncus Announced Long-Term Follow-Up Data on InterVapor, Showing Stable Long-Term Efficacy in Patients
HANGZHOU, China, Sept. 18, 2023 /PRNewswire/ -- During the 23th ERS International Congress onSeptember 11, Broncus announced long-term follow-up data about Bronchoscopic Thermal Vapor Ablation (BTVA) treatment using InterVapor®, the Company's product for the treatment of Chronic Obstructive Pulm...
Broncus Medical (02216.HK) Announces Interim Results for 2023
Product sales in China for interim FY2023 increased of 114% compared to the same period in 2022, while product commercialization is steadily advancing. HANGZHOU, China, Aug. 30, 2023 /PRNewswire/ -- On August 29, 2023, Broncus Medical (02216.HK), a leader in precise interventional diagnosis and t...
6-Month Registered Clinical Trial Data on World's First Transbronchial Pulmonary Radiofrequency Ablation System for Lung Cancer Announced, Showing Significant Efficacy
HANGZHOU, China, Aug. 7, 2023 /PRNewswire/ -- During the Chinese Medical Association 11th National Academic Conference on Respiratory Endoscopy and Interventional Pulmonology on August 5, Broncus (2216.HK) announced postoperative 6-month data of a registered clinical trial on RF II, the world's ...
BRONCUS COMPLETES THE FIRST CASE OF REGISTERED CLINICAL TRIALS OF ITS TARGETED LUNG DENERVATION RADIOFREQUENCY ABLATION SYSTEM
HANGZHOU, China, July 10, 2023 /PRNewswire/ -- Broncus Holding Corporation (HKG:2216) has completed the first case of registered clinical trials of its targeted lung denervation (''TLD'') radiofrequency ablation system. The multi-center clinical randomized controlled trial on the ''treatment of C...
Broncus Medical (02216.HK) Announces Annual Results for 2022
Product sales in China for 2022 increased 50% compared to the same period in 2021, while product development and commercialization are steadily advancing. HANGZHOU, China, March 30, 2023 /PRNewswire/ -- On March 29, 2023, Broncus Medical (02216.HK), a leader in precise interventional diagnosis an...
Broncus (02216.HK) announced interim results
The operating revenue had a year-on-year increase by 12.8% in 2022, and the loss narrowed by 62.8%, gradually forming a closed-loop model of "diagnosis + treatment+ chronic disease management" for major pulmonary diseases HANGZHOU, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, 2022, Broncus ...
BRONCUS COMPLETED SURGERIES ON THE FIRST GROUP OF PATIENTS USING ITS InterVapor®, THE THERMAL VAPOR TREATMENT SYSTEM, AFTER APPROVED FOR MARKETING IN CHINA
HANGZHOU, China, July 18, 2022 /PRNewswire/ -- Broncus Medical (02216.HK) has completed surgeries on the first group of patients using its InterVapor® (including InterVapor Generator and InterVapor Catheter, the "InterVapor®"), after it was approved for marketing inChina. This marked the official ...
Broncus Medical (02216.HK) Announces Annual Results for 2021: Operating revenue for 2021 increased 234.2% year-on-year, while product development and commercialization are steadily advancing.
HANGZHOU, China, March 30, 2022 /PRNewswire/ -- On March 29, 2022, Broncus Medical (02216.HK), the leader in precision interventional treatment for lung diseases inChina, announced its annual results announcement for the year ended December 31, 2021. During the period, the Group earned revenue of...
INTERVAPOR®, THERMAL VAPOR TREATMENT SYSTEM, APPROVED FOR MARKETING IN CHINA
HANGZHOU, China, March 21, 2022 /PRNewswire/ -- Broncus(02216HK) today is pleased to announce that InterVapor® (including InterVapor Generator and InterVapor Catheter, the "InterVapor®"), the Company's thermal vapor treatment system, has been granted approval by the National Medical Products Adm...
Broncus enter into strategic partnership with New Frontier Health Corporation /United Family Healthcare
HANGZHOU, China, Dec. 6, 2021 /PRNewswire/ -- Broncus Holding Corporation (2216.HK) ("Broncus"), the leader of minimally invasive diagnostic and therapeutic technology for solutions to different lung diseases inChina, today announced that it has entered into a strategic cooperation framework agre...
Broncus Completed the First-in-man Clinical Trial of Its Targeted Lung Denervation Radiofrequency Ablation System
HONG KONG, Sept. 30, 2021 /PRNewswire/ -- Broncus Holding Corporation ("Broncus" or the "Company") is pleased to announce that it has completed the first-in-man clinical trial of its Targeted Lung Denervation (TLD) radiofrequency ablation system, which is expected to benefit patients with chroni...
Qiming's Portfolio Company Broncus Lists on Main Board of HKEx
SHANGHAI, Sept. 24, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Broncus (SEHK:2216), a pioneer inChina's interventional pulmonology navigation device market, today listed on the main board of Hong Kong Stock Exchange. The issue price isHK$ 18.7/share, representing a market ca...
Broncus Lists on Main Board of HKEx
HONG KONG, Sept. 24, 2021 /PRNewswire/ -- On September 24, Broncus (02216.HK), a pioneer in the field of interventional pulmonology inChina, was successfully listed on the main board of the Hong Kong Stock Exchange. Broncus, founded in 2012, is a medical device company focused on the development...
